Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (Previously Presented): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of the formula:



wherein

Base is a pyrimidine base;

X is O, S, CH_2, Se, NH, N-alkyl, CHW (*R*, *S*, or racemic), $C(W)_2$, wherein W is F, Cl, Br, or I;

R^1 and R^7 are independently H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug, H-phosphonate, including stabilized H-phosphonates, acyl, including optionally substituted phenyl and lower acyl, alkyl, including lower alkyl, O-substituted carboxyalkylamino or its peptide derivatives, sulfonate ester, including alkyl or arylalkyl sulfonyl, including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted, a lipid, including a phospholipid, an L or D-amino acid (or racemic mixture), a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 is H or phosphate; R^2 is H or phosphate; R^1 and R^2 or R^7 can also be linked with cyclic phosphate group;

R^2 and $R^{2'}$ are independently H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{1-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkyl), C(O)O(C_{1-4} alkynyl), C(O)O(C_{1-4} alkenyl), O(C_{1-4} acyl), O(C_{1-4} alkyl), O(C_{1-4} alkenyl),

$S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{1-4}$ alkynyl), $S(C_{1-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{1-4}$ alkynyl), $SO(C_{1-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkynyl), $SO_2(C_{1-4}$ alkenyl), $O_3S(C_{1-4}$ acyl), $O_3S(C_{1-4}$ alkyl), $O_3S(C_{1-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{1-4}$ alkenyl), $NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkynyl), $C(O)O(C_{1-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{1-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{1-4}$ alkynyl), $S(C_{1-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{1-4}$ alkynyl), $SO(C_{1-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkynyl), $SO_2(C_{1-4}$ alkenyl), $O_3S(C_{1-4}$ acyl), $O_3S(C_{1-4}$ alkyl), $O_3S(C_{1-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{1-4}$ alkenyl), $NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$, OR^7; R^2 and $R^{2'}$ can be linked together to form a vinyl optionally substituted by one or two of N_3, CN, Cl, Br, F, I, NO_2; and

R^6 is an optionally substituted alkyl (including lower alkyl), cyano (CN), CH_3, OCH_3, OCH_2CH_3, hydroxy methyl (CH_2OH), fluoromethyl (CH_2F), azido (N_3), CHCN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or fluoro;

or its pharmaceutically acceptable salt or prodrug thereof.

Claim 2 (Currently Amended): The (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of claim 1 or its pharmaceutically acceptable salt or prodrug thereof, wherein the Base is represented by the following formula



wherein

R^3 and R^4 are independently H, halogen including F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower

alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, ~~lower hydroxyalkyl,~~ CO_2H, CO_2R', $CONH_2$, $CONHR'$, $CONR'_2$, $CH{=}CHCO_2H$, $CH{=}CHCO_2R'$; and,

R' is an optionally substituted alkyl of C_1-C_{12}, cycloalkyl, optionally substituted alkynyl of C_2-C_6, optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, ~~or, in the case of NHR' and COR', R' can be an amino acid residue.~~

Claim 3 (Previously Presented): The (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D) of claim 1 or its pharmaceutically acceptable salt or prodrug thereof,

wherein the Base is represented by the following formula



and wherein R^1 is H, R^2 is OH, $R^{2'}$ is H, R^3 is H, and R^4 is NH_2 or OH.

Claim 4 (Currently Amended): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of the formula:



wherein

the Base is represented by the following formula



R^1 and R^7 are independently H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug, H-phosphonate, including stabilized H-phosphonates, acyl, including optionally substituted phenyl and lower acyl, alkyl, including lower alkyl, O-substituted carboxyalkylamino or its peptide derivatives, sulfonate ester, including alkyl or arylalkyl sulfonyl, including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted, a lipid, including a phospholipid, an L or D-amino acid (or racemic mixture), a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 is H or phosphate; R^2 is H or phosphate; R^1 and R^2 or R^7 can also be linked with cyclic phosphate group;

R^2 and $R^{2'}$ are independently H, C_{1-4} alkyl, C_{1-4} alkenyl, C_{1-4} alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkynyl), $C(O)O(C_{1-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{1-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{1-4}$ alkynyl), $S(C_{1-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{1-4}$ alkynyl), $SO(C_{1-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkynyl), $SO_2(C_{1-4}$ alkenyl), $O_3S(C_{1-4}$ acyl), $O_3S(C_{1-4}$ alkyl), $O_3S(C_{1-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{1-4}$ alkenyl), $NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkynyl), $C(O)O(C_{1-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{1-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{1-4}$ alkynyl), $S(C_{1-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{1-4}$ alkynyl), $SO(C_{1-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkynyl), $SO_2(C_{1-4}$

alkenyl), $O_3S(C_{1-4}$ acyl), $O_3S(C_{1-4}$ alkyl), $O_3S(C_{1-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{1-4}$ alkenyl), $NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$, OR^7; R^2 and $R^{2'}$ can be linked together to form a vinyl optionally substituted by one or two of N_3, CN, Cl, Br, F, I, NO_2;

R^3 and R^4 are independently H, halogen including F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I), lower alkoxy of C_1-C_6, ~~lower hydroxyalkyl,~~ CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH=CHCO_2H$, $CH=CHCO_2R'$;

R' is an optionally substituted alkyl of C_1-C_{12} cycloalkyl, optionally substituted alkynyl of C_2-C_6, optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl~~, or, in the case of NHR' and COR', R' can be an amino acid residue;~~

R^6 is an optionally substituted alkyl (including lower alkyl), cyano (CN), CH_3, OCH_3, OCH_2CH_3, hydroxy methyl (CH_2OH), fluoromethyl (CH_2F), azido (N_3), CHCN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH_3)_2$, alkyne (optionally substituted), or fluoro;

or its pharmaceutically acceptable salt or prodrug thereof.

Claim 5 (Previously Presented): The (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D) of claim 4 or its pharmaceutically acceptable salt or prodrug thereof, wherein

the Base is represented by the following formula



and R^1 is H, R^2 is OH, $R^{2'}$ is H, R^3 is H, R^4 is NH_2 or OH, and R^6 is H.

Claim 6 (Previously Presented): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) or its pharmaceutically acceptable salt or prodrug thereof of the structure:



wherein the Base is a pyrimidine base;

X is O, S, CH_2, Se, NH, N-alkyl, CHW (*R*, *S*, or racemic), $C(W)_2$, wherein W is F, Cl, Br, or I; and,

R^1 and R^7 are independently H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug, H-phosphonate, including stabilized H-phosphonates, acyl, including optionally substituted phenyl and lower acyl, alkyl, including lower alkyl, O-substituted carboxyalkylamino or its peptide derivatives, sulfonate ester, including alkyl or arylalkyl sulfonyl, including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted, a lipid, including a phospholipid, an L or D-amino acid, a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 or R^7 is independently H or phosphate; R^1 and R^7 can also be linked with cyclic phosphate group.

Claim 7 (Currently Amended): The (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of claim 6 or its pharmaceutically acceptable salt or prodrug thereof,

wherein the Base is represented by the following formula



R^3 and R^4 are independently H, halogen including F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, ~~lower hydroxyalkyl,~~ CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, $CH{=}CHCO_2R'$; and,

R' is an optionally substituted alkyl of C_1-C_{12} cycloalkyl, optionally substituted alkynyl of C_2-C_6, optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl, ~~or, in the case of NHR' and COR', R' can be an amino acid residue.~~

Claim 8 (Previously Presented): The (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D) of claim 6 or its pharmaceutically acceptable salt or prodrug thereof,

wherein the Base is represented by the following formula



and wherein R^1 and R^7 are H, R^3 is H, and R^4 is NH_2 or OH.

Claim 9 (Currently Amended): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of the formula:



wherein the Base is



X is O, S, CH_2, Se, NH, N-alkyl, CHW (*R*, *S*, or racemic), $C(W)_2$, wherein W is F, Cl, Br, or I;

R^1 and R^7 are independently H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug, H-phosphonate, including stabilized H-phosphonates, acyl, including optionally substituted phenyl and lower acyl, alkyl, including lower alkyl, O-substituted carboxyalkylamino or its peptide derivatives, sulfonate ester, including alkyl or arylalkyl sulfonyl, including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted, a lipid, including a phospholipid, an L or D-amino acid (or racemic mixture), a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 is H or phosphate; R^2 is H or phosphate; R^1 and R^2 or R^7 can also be linked with cyclic phosphate group;

R^2 and $R^{2'}$ are independently H, $C_{1\text{-}4}$ alkyl, $C_{1\text{-}4}$ alkenyl, $C_{1\text{-}4}$ alkynyl, vinyl, N_3, CN, Cl, Br, F, I, NO_2, $C(O)O(C_{1\text{-}4}$ alkyl), $C(O)O(C_{1\text{-}4}$ alkyl), $C(O)O(C_{1\text{-}4}$ alkynyl), $C(O)O(C_{1\text{-}4}$ alkenyl), $O(C_{1\text{-}4}$ acyl), $O(C_{1\text{-}4}$ alkyl), $O(C_{1\text{-}4}$ alkenyl), $S(C_{1\text{-}4}$ acyl), $S(C_{1\text{-}4}$ alkyl), $S(C_{1\text{-}4}$ alkynyl), $S(C_{1\text{-}4}$ alkenyl), $SO(C_{1\text{-}4}$ acyl), $SO(C_{1\text{-}4}$ alkyl), $SO(C_{1\text{-}4}$ alkynyl), $SO(C_{1\text{-}4}$ alkenyl), $SO_2(C_{1\text{-}4}$ acyl), $SO_2(C_{1\text{-}4}$ alkyl), $SO_2(C_{1\text{-}4}$ alkynyl), $SO_2(C_{1\text{-}4}$ alkenyl), $O_3S(C_{1\text{-}4}$ acyl), $O_3S(C_{1\text{-}4}$ alkyl), $O_3S(C_{1\text{-}4}$ alkenyl), NH_2, $NH(C_{1\text{-}4}$ alkyl), $NH(C_{1\text{-}4}$ alkenyl),

$NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-18}$ acyl)$_2$, wherein alkyl, alkynyl, alkenyl and vinyl are optionally substituted by N_3, CN, one to three halogen (Cl, Br, F, I), NO_2, $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkyl), $C(O)O(C_{1-4}$ alkynyl), $C(O)O(C_{1-4}$ alkenyl), $O(C_{1-4}$ acyl), $O(C_{1-4}$ alkyl), $O(C_{1-4}$ alkenyl), $S(C_{1-4}$ acyl), $S(C_{1-4}$ alkyl), $S(C_{1-4}$ alkynyl), $S(C_{1-4}$ alkenyl), $SO(C_{1-4}$ acyl), $SO(C_{1-4}$ alkyl), $SO(C_{1-4}$ alkynyl), $SO(C_{1-4}$ alkenyl), $SO_2(C_{1-4}$ acyl), $SO_2(C_{1-4}$ alkyl), $SO_2(C_{1-4}$ alkynyl), $SO_2(C_{1-4}$ alkenyl), $O_3S(C_{1-4}$ acyl), $O_3S(C_{1-4}$ alkyl), $O_3S(C_{1-4}$ alkenyl), NH_2, $NH(C_{1-4}$ alkyl), $NH(C_{1-4}$ alkenyl), $NH(C_{1-4}$ alkynyl), $NH(C_{1-4}$ acyl), $N(C_{1-4}$ alkyl)$_2$, $N(C_{1-4}$ acyl)$_2$, OR^7; R^2 and $R^{2'}$ can be linked together to form a vinyl optionally substituted by one or two of N_3, CN, Cl, Br, F, I, NO_2;

R^3 and R^4 are independently H, halogen including F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, $CH{=}CHCO_2H$, $CH{=}CHCO_2R'$; and,

R' is an optionally substituted alkyl of C_1-C_{12}, cycloalkyl, optionally substituted alkynyl of C_2-C_6, optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl~~, or, in the case of NHR' and COR', R' can be an amino acid residue;~~

R^6 is an optionally substituted alkyl (including lower alkyl), cyano (CN), CH_3, OCH_3, OCH_2CH_3, hydroxy methyl (CH_2OH), fluoromethyl (CH_2F), azido (N_3), CHCN, CH_2N_3, CH_2NH_2, CH_2NHCH_3, $CH_2N(CH3)_2$, alkyne (optionally substituted), or fluoro;

or its pharmaceutically acceptable salt or prodrug thereof.

Claim 10 (Currently Amended): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D or β-L) of the formula



wherein the Base is



R^1 and R^7 are independently H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug, H-phosphonate, including stabilized H-phosphonates, acyl, including optionally substituted phenyl and lower acyl, alkyl, including lower alkyl, O-substituted carboxyalkylamino or its peptide derivatives, sulfonate ester, including alkyl or arylalkyl sulfonyl, including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted, a lipid, including a phospholipid, an L or D-amino acid (or racemic mixture), a carbohydrate, a peptide, a cholesterol, or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 is H or phosphate; R^2 is H or phosphate; R^1 and R^2 or R^7 can also be linked with cyclic phosphate group;

R^3 and R^4 are independently H, halogen including F, Cl, Br, I, OH, OR', SH, SR', NH_2, NHR', NR'$_2$, lower alkyl of C_1-C_6, halogenated (F, Cl, Br, I) lower alkyl of C_1-C_6, lower alkenyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkenyl of C_2-C_6, lower alkynyl of C_2-C_6, halogenated (F, Cl, Br, I) lower alkynyl of C_2-C_6, lower alkoxy of C_1-C_6, halogenated (F, Cl, Br, I) lower alkoxy of C_1-C_6, ~~lower hydroxyalkyl,~~ CO_2H, CO_2R', $CONH_2$, CONHR', CONR'$_2$, CH=CHCO$_2$H, CH=CHCO$_2$R';

R' is an optionally substituted alkyl of C_1-C_{12} cycloalkyl, optionally substituted alkynyl of C_2-C_6, optionally substituted lower alkenyl of C_2-C_6, or optionally substituted acyl~~, or, in the case of NHR' and COR', R' can be an amino acid residue;~~

or its pharmaceutically acceptable salt or prodrug thereof.

Claim 11 (Original): A (2'*R*)-2'-deoxy-2'-fluoro-2'-*C*-methyl nucleoside (β-D) or its pharmaceutically acceptable salt or prodrug thereof of the formula:



Claims 12-15 (Canceled).

Claim 16 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 17 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 2 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 18 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 3 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 19 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 20 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 21 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 22 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 23 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 8 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 24 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 9 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 25 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claim 26 (Previously Presented): A pharmaceutical composition comprising the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug and a pharmaceutically acceptable carrier.

Claims 27-30 (Canceled).

Claim 31 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 32 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 2 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 33 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 3 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 34 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 35 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 36 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 37 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 38 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 8 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 39 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of

claim 9 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 40 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 41 (Withdrawn): A method for the treatment or prophylaxis of hepatitis C infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claims 42-45 (Canceled).

Claim 46 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 47 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 2 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 48 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of

claim 3 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 49 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 50 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 51 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 52 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 53 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 8 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 54 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 9 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 55 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 56 (Withdrawn): A method for the treatment or prophylaxis of a rhinovirus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claims 57-60 (Canceled).

Claim 61 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 62 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 2 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 63 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 3 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 64 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 65 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 66 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 67 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 68 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 8 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 69 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 9 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 70 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 71 (Withdrawn): A method for the treatment or prophylaxis of a yellow fever virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claims 72-75 (Canceled).

Claim 76 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 77 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 2 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 78 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 3 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 79 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 80 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 81 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 82 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 83 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of

claim 8 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 84 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 9 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 85 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 86 (Withdrawn): A method for the treatment or prophylaxis of a West Nile virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claims 87-90 (Canceled).

Claim 91 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 1 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 92 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of

claim 2 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 93 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 3 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 94 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 4 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 95 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 5 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 96 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 6 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 97 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 7 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 98 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 8 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 99 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 9 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 100 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 10 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claim 101 (Withdrawn): A method for the treatment or prophylaxis of a Dengue virus infection comprising administering to a host an antivirally effective amount of the nucleoside of claim 11 or its pharmaceutically acceptable salt or prodrug optionally in a pharmaceutically acceptable carrier.

Claims 102-105 (Canceled).

Claim 106 (Withdrawn): The method of 31, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor

including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claim 107 (Withdrawn): The method of 41, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claims 108-109 (Canceled).

Claim 110 (Withdrawn): The method of 46, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated

interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claim 111 (Withdrawn): The method of 56, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claims 112-113 (Canceled).

Claim 114 (Withdrawn): The method of 61, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a

pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claim 115 (Withdrawn): The method of 71, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claims 116-117 (Canceled).

Claim 118 (Withdrawn): The method of 76, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claim 119 (Withdrawn): The method of 86, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claims 120-121 (Canceled).

Claim 122 (Withdrawn): The method of 91, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claim 123 (Withdrawn): The method of 101, wherein the antivirally effective amount of the nucleoside is administered in combination or alternation with at least one treatment selected from the group consisting of: interferon, including interferon alpha 2a, interferon alpha 2b, a pegylated interferon, interferon beta, interferon gamma, interferon tau and interferon omega; an interleukin, including interleukin 10 and interleukin 12; ribavirin; interferon alpha or pegylated interferon alpha in combination with ribavirin or levovirin; levovirin; a protease inhibitor including an NS3 inhibitor, a NS3-4A inhibitor; a helicase inhibitor; a polymerase inhibitor including HCV RNA polymerase and NS5B polymerase inhibitor; gliotoxin; an IRES inhibitor; and antisense oligonucleotide; a thiazolidine derivative; a benzanilide, a ribozyme; another nucleoside, nucleoside prodrug or nucleoside derivative; a 1-amino-alkylcyclohexane; an antioxidant including vitamin E; squalene; amantadine; a bile acid; N-(phosphonoacetyl)-L-aspartic acid; a benzenedicarboxamide; polyadenylic acid; a benzimidazoles; thymosin; a beta

tubulin inhibitor; a prophylactic vaccine; an immune modulator, an IMPDH inhibitor; silybin-phosphatidylcholine phytosome; and mycophenolate.

Claims 124-125 (Canceled).

Claim 126 (Withdrawn): A method of synthesizing the nucleoside of claim 11, which comprises

glycosylating the pyrimidine with a compound having the following structure:



1-4

wherein R is lower alkyl, acyl, benzoyl, or mesyl; and Pg is any acceptable protecting group consisting of but not limited to C(O)-alkyl, C(O)Ph, C(O)aryl, CH_3, CH_2-alkyl, CH_2-alkenyl, CH_2Ph, CH_2-aryl, CH_2O-alkyl, CH_2O-aryl, SO_2-alkyl, SO_2-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, or both Pg's may come together to for a 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

Claim 127 (Withdrawn): A method of synthesizing the nucleoside of claim 1, which comprises

selectively deprotecting the 3'-OPg or the 5'-OPg of a compound having the following structure:



2-5

wherein, Pg is independently any pharmaceutically acceptable protecting group selected from the group consisting of C(O)-alkyl, C(O)Ph, C(O)aryl, CH_3, CH_2-alkyl, CH_2-alkenyl, CH_2Ph, CH_2-aryl, CH_2O-alkyl, CH_2O-aryl, SO_2-alkyl, SO_2-aryl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, or both Pg's may come together to for a 1,3-(1,1,3,3-tetraisopropyldisiloxanylidene).

Claims 128-129 (Canceled).